Spending 200 million, Shaanxi's richest couple enters the "Rocket Satellite" race

21st Century Business Herald Reporter Ling Chen

Recently, with the announcement of a joint venture company, Shaanxi’s richest man Yan Jianya and his wife have officially thrown their chips into the high-barrier commercial aerospace track.

On March 16, Sanjiao Defense (300775.SZ) announced plans to establish Western Aerospace Technology (Shaanxi) Co., Ltd. (tentative name) (hereinafter referred to as: Aerospace Technology) together with Xite Testing, Ruituo Energy, and Shaanxi Aerospace Institute. This joint venture, with a registered capital of 500 million yuan (tentative), will focus on the star-rocket sector.

It is worth noting that Yan Jianya and Fan Daidi own two controlling listed companies: Juzo Biotech and Sanjiao Defense.

The investment story of Yan Jianya and his wife is a typical high-tech barrier-driven logic. On the consumer side, led by Fan Daidi, Juzo Biotech has continuously obtained registration certificates for Class III medical devices of recombinant collagen, gaining compliance and a competitive edge in the B-end market. Meanwhile, through technology licensing collaborations with foreign companies, it has enabled Chinese original biotech to “go abroad by ship.”

On the industrial side, Yan Jianya relies on Sanjiao Defense’s scarce position in large aerospace forgings to extend upstream into titanium alloy materials and downstream into satellite rocket complete machine manufacturing.

At the historic intersection where commercial aerospace is moving toward “star-rocket integration,” Yan Jianya and his wife are attempting to outline a second growth curve in aerospace manufacturing through deep integration of industry and finance outside the consumer field.

Solidly Sitting as the Largest Shareholder

From the announcement, all parties in the joint venture show high strategic expectations for Aerospace Technology. Its business scope covers the entire industry chain, including satellite design and manufacturing, carrier rocket R&D, manufacturing, testing, launch, as well as satellite telemetry, tracking, data application, and system integration.

Looking at the equity structure, this investment approach is very clear. Sanjiao Defense, under Yan Jianya, has performed actively, investing 200 million yuan for a 40% stake, becoming the largest shareholder.

Notably, Sanjiao Defense’s main business already involves aerospace and aviation component products.

Regarding recent progress on major aerospace projects, during an investor relations event on February 2, 2026, a company representative from Sanjiao Defense publicly responded: “The digital integration center project for aerospace has recently started construction, and assembly work for the first C919 aircraft’s fuselage sections has already begun.”

The representative also pointed out that this project will promote the extension of the company’s manufacturing industry chain, increase product added value, strengthen and expand the company’s advantages in the domestic aviation field, and enhance its industrial competitiveness.

From component suppliers to full industry chain coverage, the new joint venture, Aerospace Technology, is clearly a key step in Yan Jianya’s layout in the aerospace field.

Focusing on other joint venture partners of Aerospace Technology, Xite Testing is a provider of aerospace and high-end equipment inspection, testing, and intelligent manufacturing services, proposing and practicing the “super OEM for commercial aerospace” model.

Shaanxi Aerospace Institute is a state-owned R&D organization led by Northwestern Polytechnical University, jointly established with the Fourth and Sixth Institutes of China Aerospace Science and Industry Corporation and China Aero-Engine Corporation Xian Aero Engine. As the “national team” and “central hub” in the domestic aerospace propulsion field, it serves as a critical link connecting core technology, government resources, and commercial markets.

Sanjiao Defense explicitly stated that this investment aims to cultivate new growth points, optimize the company’s industrial structure, improve core competitiveness and sustainable development capacity, and help the company achieve breakthroughs in high-end manufacturing and strategic emerging industries.

The company also issued a risk warning, noting that while the short-term impact on current financial data and operating performance is unlikely, there are multiple uncontrollable factors in the future, making profitability difficult to predict, and there is a risk that investment returns may not meet expectations.

Juzo Biotech “Sailing Abroad” for New Growth

If commercial aerospace is Yan Jianya’s “starry sea,” then Juzo Biotech is the “cash cow” under Professor Fan Daidi and Yan Jianya’s wife and husband, which is thriving.

Against the backdrop of declining traffic dividends and price war anxiety in the skincare industry, Juzo Biotech is attempting to evolve from a “consumer goods company” in the eyes of the public into a “medical technology enterprise” through fundamental breakthroughs in technological barriers.

The key turning point lies in obtaining the “medical device license” and continuous approval of key products.

According to information from the National Medical Products Administration’s Center for Medical Device Evaluation, Shaanxi Juzo Biotech’s application for the “recombinant collagen lyophilized fiber” medical device combination was accepted on June 13, 2025.

On October 23, 2025, Juzo Biotech’s first “recombinant Type I alpha-1 collagen lyophilized fiber” was officially approved for market. Subsequently, on January 15, 2026, the company’s “recombinant Type I alpha-1 collagen and sodium hyaluronate composite solution” was approved as the world’s first such composite implant product.

These two Class III medical device registrations are highly valuable. Previously, in the medical aesthetic injection field, Jinbo Biotech was the only company with three certificates for recombinant humanized collagen. With Juzo Biotech’s efforts, this situation is expected to further break through.

For Juzo Biotech, moving from “cosmetics” to “medical devices” is not only an upgrade in compliance but also a rebuilding of profit barriers.

In the B-end medical aesthetic market, Juzo Biotech now has the capability to compete head-to-head with Jinbo Biotech. Unlike simple discount marketing, these products with medical device qualifications are “hardcore” conditions for opening doors to global medical institutions.

To cope with domestic red ocean competition, Juzo Biotech has also launched a “sailing abroad by ship” strategy. By partnering with Swedish biotech and medical device company Nordberg Medical, leveraging Juzo Biotech’s proprietary synthetic biology platform, they jointly promote the global development and commercialization of recombinant collagen in aesthetic medicine and biomedicine. This model avoids the long cycle of building channels independently, enabling direct technology monetization and global branding.

As of March 19, 2026, Juzo Biotech’s stock price was 30.86 HKD, with a total market value of 33.05 billion HKD.

Yan Jianya and his wife, on one hand, are pushing Juzo Biotech into high-premium professional medical tracks through “medical research co-creation,” and on the other hand, channeling funds into high-barrier military and aerospace sectors. Although Juzo Biotech’s market value fluctuates, it still forms a stable dual-core with Sanjiao Defense—“one civilian, one military; one light, one heavy.”